


## Appendix

### Appendix Exhibit 1


#### Trends in Hospital Ambulatory Clinic Market Shares: Enbrel and its Biosimilars



Source: Base Nationale ATIH du Programme de Médicalisation des Systèmes d'Informations et des Médicaments.

## Appendix Exhibit 2

### Trends in Hospital Ambulatory Clinic Market Shares: Humira and its Biosimilars



Source: Base Nationale ATIH du Programme de Médicalisation des Systèmes d'Informations et des Médicaments

### Appendix Exhibit 3

#### Trends in Hospital Ambulatory Clinic Sales for Biologics and Biosimilars (Euros)

|                      | 2015        | 2019       |
|----------------------|-------------|------------|
| Remicade             | 276,360,219 | 33,806,292 |
| Remicade biosimilars | 6,673,407   | 59,475,751 |
| Enbrel               | 251,448     | 49,781     |
| Enbrel biosimilars   | 0           | 36,840     |
| Humira               | 4,038,542   | 730,580    |
| Humira biosimilars   | 0           | 50,670     |

Source: Base Nationale ATIH du Programme de Médicalisation des Systèmes d'Informations et des Médicaments. All figures are measured in Euros.